Loading...
•
Jun 30, 2020
United Therapeutics Q2 2020 Earnings Report
United Therapeutics' financial performance was announced for Q2 2020, revealing a mix of challenges and successes.
Key Takeaways
United Therapeutics reported a decrease in total revenues by 3% compared to the same quarter last year, with net income also declining by 48%. However, Orenitram revenue saw a significant increase of 40% year-over-year. The company is preparing for potential growth with upcoming product launches and label expansions.
Total revenues decreased by 3% year-over-year, totaling $362 million.
Net income declined by 48% compared to the same quarter last year, reaching $107.1 million.
Orenitram revenue increased by 40% year-over-year, driven by increased quantities sold after a label update.
The company submitted the INCREASE study results to the FDA, anticipating revised labeling for Tyvaso.
United Therapeutics
United Therapeutics
United Therapeutics Revenue by Segment
Revenue by Segment
Tyvaso Revenue
CapyFin.comRemodulin Revenue
CapyFin.comOrenitram Revenue
CapyFin.comUnituxin Revenue
CapyFin.comAdcirca Revenue
CapyFin.com Forward Guidance
United Therapeutics is focusing on launching new products and expanding the label for Tyvaso. However, the COVID-19 pandemic has caused delays in the commercial sales of Remunity Pump.
Positive Outlook
- Tyvaso is expected to grow due to the INCREASE study results.
- The INCREASE study results were submitted to the FDA, expecting revised labeling reflecting the outcome.
- The company is working to commence commercial sales of the Remunity Pump in the near-term.
- Clinical studies remain open, and enrollment of new patients has resumed at select study sites for certain studies.
- The company is expanding efforts to enter into contracts with additional clinical study sites and complete other site activation activities for certain studies.
Challenges Ahead
- Manufacturing and regulatory requests are causing delays in the launch of Remunity Pump and Implantable System for Remodulin.
- The timing of commercial sales of Remunity Pump has been delayed due to pandemic-related issues.
- The FDA issued a complete response letter (CRL) related to the NDA for Trevyent.
- The launch of Implantable System for Remodulin is delayed until 2021.
- Completion and data readouts for several ongoing and planned studies are expected to be delayed due to the pandemic.
Revenue & Expenses
Visualization of income flow from segment revenue to net income